Scholarlink

Background <p>Cancer patients face a high risk of thromboembolic complications due to disease-, treatment-, and patient-related factors. Chemotherapy regimens such as anthracyclines and alkylating agents can increase both venous and arterial thrombosis, leading to significant morbidity.</p> Case summary <p>A 44-year-old woman with invasive ductal carcinoma of the right breast underwent right mastectomy and received adjuvant chemotherapy with doxorubicin (60&#xa0;mg/m²) and cyclophosphamide (600&#xa0;mg/m²). Five days after her second treatment cycle, she presented with chest pain. Electrocardiography showed inferolateral ST-segment elevation, and echocardiography revealed a left ventricular ejection fraction (LVEF) of 38%. Coronary angiography demonstrated total occlusion of the distal left anterior descending and circumflex arteries. She was treated with dual antiplatelet therapy, low-molecular-weight heparin, and a glycoprotein IIb/IIIa inhibitor. Follow-up angiography on day five showed complete thrombus resolution and restoration of TIMI III flow. During long-term follow-up, her left ventricular function recovered (LVEF 50%) and her cancer remained in complete remission.</p> Conclusion <p>This case illustrates a rare but clinically important complication of adjuvant doxorubicin–cyclophosphamide therapy, presenting as subacute inferolateral myocardial infarction secondary to coronary thrombosis. Awareness of this potential adverse effect and early management are crucial for improved outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chemotherapy-associated coronary thrombosis presenting as acute coronary syndrome in breast cancer: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月9日

查看全文
  • Oya Imadoglu,
  • Emre Emrah Demirci,
  • Sefa Sural

摘要

Background

Cancer patients face a high risk of thromboembolic complications due to disease-, treatment-, and patient-related factors. Chemotherapy regimens such as anthracyclines and alkylating agents can increase both venous and arterial thrombosis, leading to significant morbidity.

Case summary

A 44-year-old woman with invasive ductal carcinoma of the right breast underwent right mastectomy and received adjuvant chemotherapy with doxorubicin (60 mg/m²) and cyclophosphamide (600 mg/m²). Five days after her second treatment cycle, she presented with chest pain. Electrocardiography showed inferolateral ST-segment elevation, and echocardiography revealed a left ventricular ejection fraction (LVEF) of 38%. Coronary angiography demonstrated total occlusion of the distal left anterior descending and circumflex arteries. She was treated with dual antiplatelet therapy, low-molecular-weight heparin, and a glycoprotein IIb/IIIa inhibitor. Follow-up angiography on day five showed complete thrombus resolution and restoration of TIMI III flow. During long-term follow-up, her left ventricular function recovered (LVEF 50%) and her cancer remained in complete remission.

Conclusion

This case illustrates a rare but clinically important complication of adjuvant doxorubicin–cyclophosphamide therapy, presenting as subacute inferolateral myocardial infarction secondary to coronary thrombosis. Awareness of this potential adverse effect and early management are crucial for improved outcomes.